Venue | Press Room | Subscribe | Site Map
TechConnect Summit 2006
Home | About the Summit | Program | Advisory Boards | About TechConnect

Producing Sponsor


Platinum Sponsor

Welsh & Katz, Ltd.

Gold Sponsor

ISTC International Science & Technology Center

Ventures Enabling Sponsor

Atomic Venture Partners

Press Sponsor

Business Wire

Partnering Sponsor


Supporting Organizations

Boston University
Midwest Research University Network

Media Sponsors

(joint with Nanotech 2006) Nature
R&D Magazine

Summit News

Event Contact

Jennifer Rocha
955 Massachusetts Ave. #313
Cambridge, MA 02139
Phone: (774) 249-8514


Location:CT, US
Speaker:Thomas T. Chen
Title:Chief Medical Scientist
Primary Industry:Pharma & Biotech
Executive Summary: An innovative approach to cancer therapy. EP Therapeutics, Inc., (EPT) is engaged in the development of a revolutionary new class of cancer treatments that will provide safer alternative therapies by eliminating the need for chemotherapy or radiation protocols.The company is engaged in the development of new treatments for the management of epithelial cancers based on a unique, patented peptide (EPT-peptide). Numerous in vitro and in vivo studies have demonstrated that EPT-peptide and its gene possess properties that suppress growth, metastasis and angiogenesis and result in the induction of programmed cell death in many cancer types, including breast, ovary, colon, liver, brain and prostate. In addition, EPT-peptide possesses the attributes necessary for an ideal cancer treatment instrument.
Venture is:A-Round


Home | About the Summit | Program | Advisory Boards | About TechConnect
Terms of use | Privacy policy | Contact | TechConnect Home
© 2005 TechConnect. All rights reserved.